Published in PLoS Biol on November 15, 2011
Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci U S A (2013) 1.57
Global nutrition research: nutrition and breast cancer prevention as a model. Nutr Rev (2013) 1.43
Edgotype: a fundamental link between genotype and phenotype. Curr Opin Genet Dev (2013) 1.12
Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset. Proc Natl Acad Sci U S A (2014) 0.95
Targeting protein for xenopus kinesin-like protein 2 (TPX2) regulates γ-histone 2AX (γ-H2AX) levels upon ionizing radiation. J Biol Chem (2012) 0.93
Hyaluronan and RHAMM in wound repair and the "cancerization" of stromal tissues. Biomed Res Int (2014) 0.89
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Front Biosci (Landmark Ed) (2014) 0.88
Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. Oncotarget (2013) 0.87
The BRCA1 Breast Cancer Suppressor: Regulation of Transport, Dynamics, and Function at Multiple Subcellular Locations. Scientifica (Cairo) (2012) 0.85
Therapeutic targeting of hyaluronan in the tumor stroma. Cancers (Basel) (2012) 0.85
Building risk-on-a-chip models to improve breast cancer risk assessment and prevention. Integr Biol (Camb) (2013) 0.83
The cytoskeletal protein RHAMM and ERK1/2 activity maintain the pluripotency of murine embryonic stem cells. PLoS One (2013) 0.83
Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One (2015) 0.82
TPX2 impacts acetylation of histone H4 at lysine 16: implications for DNA damage response. PLoS One (2014) 0.81
ANKRD26 and its interacting partners TRIO, GPS2, HMMR and DIPA regulate adipogenesis in 3T3-L1 cells. PLoS One (2012) 0.81
Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers. J Cancer Res Clin Oncol (2014) 0.80
A case of cervical cancer expressed three mRNA variant of Hyaluronan-mediated motility receptor. Int J Clin Exp Pathol (2014) 0.78
Carcinoma Cell Hyaluronan as a "Portable" Cancerized Prometastatic Microenvironment. Cancer Res (2016) 0.77
Spatial regulation of Aurora A activity during mitotic spindle assembly requires RHAMM to correctly localize TPX2. Cell Cycle (2014) 0.77
Uncovering the dual role of RHAMM as an HA receptor and a regulator of CD44 expression in RHAMM-expressing mesenchymal progenitor cells. Front Cell Dev Biol (2015) 0.77
Yeast Augmented Network Analysis (YANA): a new systems approach to identify therapeutic targets for human genetic diseases. F1000Res (2014) 0.77
Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison. Front Oncol (2014) 0.76
HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells. Breast Cancer (Dove Med Press) (2016) 0.75
Prognostic significance of CD168 overexpression in colorectal cancer. Oncol Lett (2016) 0.75
Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability. PLoS One (2017) 0.75
RHAMM deficiency disrupts folliculogenesis resulting in female hypofertility. Biol Open (2015) 0.75
Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance. Front Oncol (2016) 0.75
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc (2009) 38.62
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (2003) 18.51
Generation of a functional mammary gland from a single stem cell. Nature (2006) 18.30
Purification and unique properties of mammary epithelial stem cells. Nature (2006) 15.98
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88
Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A (1992) 8.69
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med (2004) 6.40
Phospho-regulation of kinetochore-microtubule attachments by the Aurora kinase Ipl1p. Cell (2002) 5.91
A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet (2001) 5.02
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res (2005) 4.79
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell (2003) 4.51
Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst (2006) 4.47
Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev (2009) 4.29
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell (2011) 4.08
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Phosphoproteome analysis of the human mitotic spindle. Proc Natl Acad Sci U S A (2006) 3.56
The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell (2006) 3.46
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol (2006) 3.24
Anchorage of microtubule minus ends to adherens junctions regulates epithelial cell-cell contacts. Cell (2008) 2.99
A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol (2005) 2.65
Basal-like breast cancer and the BRCA1 phenotype. Oncogene (2006) 2.62
Efficient multipoint linkage analysis through reduction of inheritance space. Am J Hum Genet (2001) 2.58
Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev (2002) 2.51
Identification of alternative splicing markers for breast cancer. Cancer Res (2008) 2.51
Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol (2008) 2.46
BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol (2004) 2.46
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol (2008) 2.41
The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet (2002) 2.38
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
BRCA1 functions as a breast stem cell regulator. J Med Genet (2004) 1.92
Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 1.91
Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments. Integr Biol (Camb) (2008) 1.82
Altered centrosome structure is associated with abnormal mitoses in human breast tumors. Am J Pathol (1999) 1.82
A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet (1998) 1.77
Retracted BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem (2004) 1.77
Epithelial progenitors in the normal human mammary gland. J Mammary Gland Biol Neoplasia (2005) 1.74
Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res (2006) 1.69
Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res (2009) 1.66
Axon extension occurs independently of centrosomal microtubule nucleation. Science (2010) 1.63
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res (2009) 1.59
The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat (2006) 1.58
XRHAMM functions in ran-dependent microtubule nucleation and pole formation during anastral spindle assembly. Curr Biol (2004) 1.56
Maximal extraction of biological information from genetic interaction data. PLoS Comput Biol (2009) 1.42
Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. J Clin Invest (2009) 1.37
RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell (2003) 1.35
Centrosomal microtubule nucleation activity is inhibited by BRCA1-dependent ubiquitination. Mol Cell Biol (2005) 1.33
Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol (2006) 1.20
Targeting aurora kinases as therapy in multiple myeloma. Blood (2007) 1.19
The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle (2006) 1.17
Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res (2005) 1.16
Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst (2006) 1.13
Microtubule plus-end and minus-end capture at adherens junctions is involved in the assembly of apico-basal arrays in polarised epithelial cells. Cell Motil Cytoskeleton (2009) 1.11
Factors necessary to produce basoapical polarity in human glandular epithelium formed in conventional and high-throughput three-dimensional culture: example of the breast epithelium. BMC Biol (2009) 1.10
Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol (2009) 1.07
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood (2004) 1.07
Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation. Cancer Res (2007) 1.07
RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J Biol Chem (2010) 1.06
The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. J Cell Sci (1999) 1.06
Centrosome-related genes, genetic variation, and risk of breast cancer. Breast Cancer Res Treat (2010) 1.03
CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. Hum Mol Genet (2002) 1.01
The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells. J Pathol (2001) 0.97
BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters. Cancer Res (2011) 0.97
Getting to the root of BRCA1-deficient breast cancer. Cell Stem Cell (2009) 0.95
Frequency control of cell cycle oscillators. Curr Opin Genet Dev (2010) 0.87
Identification of a three-gene expression signature of poor-prognosis breast carcinoma. Mol Cancer (2004) 0.86
Genetic interactions: the missing links for a better understanding of cancer susceptibility, progression and treatment. Mol Cancer (2008) 0.84
Hyaluronan-mediated motility receptor gene single nucleotide polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 0.84
Nuclei of non-muscle cells bind centrosome proteins upon fusion with differentiating myoblasts. PLoS One (2009) 0.82
Regulation of ciliary differentiation of human respiratory epithelial cells by the receptor for hyaluronan-mediated motility on hyaluronan-based biomaterials. Biomaterials (2010) 0.76
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Family-group names in Coleoptera (Insecta). Zookeys (2011) 25.51
Towards a proteome-scale map of the human protein-protein interaction network. Nature (2005) 24.76
International network of cancer genome projects. Nature (2010) 20.35
Landscape of transcription in human cells. Nature (2012) 20.18
The human disease network. Proc Natl Acad Sci U S A (2007) 19.58
GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res (2012) 19.19
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet (2007) 19.08
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
The HUPO PSI's molecular interaction format--a community standard for the representation of protein interaction data. Nat Biotechnol (2004) 16.08
A map of the interactome network of the metazoan C. elegans. Science (2004) 15.60
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res (2012) 15.41
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet (2004) 14.31
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
A mitochondrial protein compendium elucidates complex I disease biology. Cell (2008) 13.51
Evidence for dynamically organized modularity in the yeast protein-protein interaction network. Nature (2004) 13.27
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Drug-target network. Nat Biotechnol (2007) 11.15
Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype. Nature (2004) 11.03
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88
High-quality binary protein interaction map of the yeast interactome network. Science (2008) 10.65
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64
Biallelic inactivation of BRCA2 in Fanconi anemia. Science (2002) 9.31
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
Characterization of mammalian selenoproteomes. Science (2003) 9.07
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
Transcriptome and genome sequencing uncovers functional variation in humans. Nature (2013) 8.89
A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell (2006) 8.61
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet (2009) 8.30
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24